The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer

Baranyai, Zsolt; Krzystanek, Marcin; Jósa, Valéria; Dede, Kristóf; Ágoston, Emese Irma; Szász, A. Marcell; Sinkó, Dániel; Szarvas, V.; Salamon, Ferenc; Eklund, Aron C.; Szállási, Zoltán; Jakab, Ferenc

doi:10.1160/th13-08-0632

Cited by 54 publications

(45 citation statements)

References 46 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[16] As for PLR, owing to the variance in the study design or relatively limited sample sizes, some research showed a decreased survival in patients with elevated PLR, [17–24] whereas others did not demonstrate the relationship between prognosis and PLR. [15,25–30] Until now, there was no meta-analysis accessing the prognostic utility of PLR in patients with CRC.…”

Section: Introductionmentioning

confidence: 99%

Prognostic role of platelet–lymphocyte ratio in colorectal cancer

Tan

et al. 2016

Medicine

View full text Add to dashboard Cite

Many studies have been reported that platelet–lymphocyte ratio (PLR) may be associated with the prognosis of colorectal cancer (CRC), but the results are inconsistent. Current opinion on the prognostic role of the PLR in CRC is inconsistent and inconclusive. Therefore, we conduct a meta-analysis that combines these studies and to identify the prognostic value of PLR in patients with CRC. Data were retrieved from PubMed, EMBASE, Cochrane Library, and Web of Science databases that came from inception through January 2016. We extracted data from the characteristics of each study and analyzed the relationship between PLR and overall survival (OS), disease-free survival (DFS), or other prognosis in patients with CRC by using the hazard ratio (HR) and 95% confidence intervals (95% CIs). Of the 256 identified studies, 15 studies were included and a total of 3991 patients were included. In a meta-analysis, patients with an elevated PLR had a significantly lower OS (pooled HR, 1.53; 95% CI, 1.24–1.89; P ≤ 0.001), DFS (pooled HR, 1.68; 95% CI, 1.07–2.62; P = 0.023). Even after sensitivity analyses and trim and fill method, high PLR remains significantly predictive poorer OS, but not DFS. In addition, our meta-analysis indicated that increased PLR is also significantly associated with the poor tumor differentiation [odds ratio (OR) 2.12; 95% CI, 1.45–3.08, P < 0.001)], the propensity toward depth of infiltration (OR 1.69; 95% CI, 1.20–2.39, P = 0.003), and recurrence in patients with CRC (HR, 2.71; 95% CI, 1.31–5.60, P = 0.005). This meta-analysis suggested that a high peripheral blood PLR can be used as a predictor of OS connected with clinicopathological parameters in patients with CRC, not DFS. These ratios may thus contribute to inform more personalized treatment decisions and predict treatment outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic role of platelet–lymphocyte ratio in colorectal cancer

Tan

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…Recently, an increasing number of studies have focused on the prognostic value of an elevated platelet-to-lymphocyte ratio (PLR) in patients with cancer [8,9]. Although PLR had been widely investigated in terms of their prognostic value on cancer survival outcomes [10,11], there are few literature reporting whether PLR is a predictor of venous thromboembolism in cancer patients. To our knowledge, only one literature reported the clinical value of the PLR at the time of VTE diagnosis, in which Ferroni et al found that PLR can be a predictor for response to anticoagulation and survival [12].…”

Section: Introductionmentioning

confidence: 99%

Platelet-lymphocyte ratio is a predictor of venous thromboembolism in cancer patients

Yang

Liu

2015

Thrombosis Research

View full text Add to dashboard Cite

“…All patients that received adjuvant chemotherapy were treated with a fluoropyrimidine-based regimen, in the form of either single-agent oral capecitabine or intravenous 5-fluorouracil (5-FU), or as combination chemotherapy with FOLFOX (bolus and infusional 5-FU with oxaliplatin). Gene expression analyses have confirmed distinct molecular profiles for colorectal and appendiceal cancer [11,15]. The marked difference in the clinical behavior of these two entities further corroborates their distinct biologies and challenges the dogma of using colorectal cancer regimens for appendiceal cancer.…”

Section: Discussionmentioning

confidence: 95%

“…Previous studies have found elevated preoperative tumor marker levels (CEA, CA 19-9 and CA125) to be associated with an increased risk of recurrence and reduced survival after complete cytoreductive surgery [9,10]. There is increasing evidence that a systemic inflammatory response is of prognostic value in various cancers [11,12]. Absolute lymphocyte count (ALC) is considered a surrogate marker for the level of immunosuppression and nutritional status of patients and a prognostic factor for survival and recurrence in several cancers.…”

Section: Introductionmentioning

confidence: 99%

“…Absolute lymphocyte count (ALC) is considered a surrogate marker for the level of immunosuppression and nutritional status of patients and a prognostic factor for survival and recurrence in several cancers. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been used as indices of inflammation, and numerous studies have identified elevated NLR or PLR as adverse prognostic factors in cancers [11-13]. The aim of this study was to determine prognostic factors, including markers of systemic inflammation, for survival in a cohort of patients with stage III and IV appendiceal adenocarcinomas who were referred to a tertiary care center for HIPEC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors for survival in advanced appendiceal cancers

Khan

Diep

Tuttle

et al. 2017

CBM

View full text Add to dashboard Cite

BACKGROUND Appendiceal cancer is a rare malignancy. The optimal pathologic classification and prognostic factors for survival and treatment strategies remain poorly understood. OBJECTIVE The aim of this retrospective cohort study was to determine prognostic factors, including markers of systemic inflammation, for survival in a cohort of patients with advanced appendiceal adenocarcinomas. METHODS The study included patients with advanced appendiceal carcinoma that were treated between January 2006 and June 2012. The associations between age, gender, histopathologic subtype of appendiceal malignancy and treatment with heated intraperitoneal chemotherapy (HIPEC) and overall survival (OS) were assessed. The relationship between various markers of inflammation (platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio) and OS was also evaluated. RESULTS A total of 49 patients met eligibility criteria. Female gender and low-grade adenocarcinoma were associated with increased OS. These data suggest that the use of HIPEC treatment may also be associated with improved OS, but the difference was not statistically significant (HR = 0.37 [0.12–1.18], p = 0.09). We found no evidence of an association between markers of inflammation at diagnosis and OS. CONCLUSIONS Histopathologic subtype and gender are associated with OS in patients with advanced appendiceal carcinoma. Baseline platelet levels, NLR, and PLR do not appear to be predictive of OS in this setting.

show abstract

The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer

Cited by 54 publications

References 46 publications

Prognostic role of platelet–lymphocyte ratio in colorectal cancer

Prognostic role of platelet–lymphocyte ratio in colorectal cancer

Platelet-lymphocyte ratio is a predictor of venous thromboembolism in cancer patients

Prognostic factors for survival in advanced appendiceal cancers

Contact Info

Product

Resources

About